ChromaDex Company

ChromaDex has developed a proprietary form of nicotinamide riboside (NR), a metabolic precursor of NAD+, which is a critical part of cellular functioning that declines with age. The company has conducted human clinical trials of its compound, showing that it increases NAD+ levels in humans, and it has been found to be safe by the FDA.

Founded Date: 1999
Headquarters: United States
Technology: Cancer
Employee Number: 101-250
Industry: Longevity
Estimated Revenue: $10M to $50M
Number Of Exists: N/A
Funding Status: IPO
Investor Type: N/A
Investment Stage: N/A